Pergoverisr in Assisted Reproductive Technology

- The folks at Merck KGaA are studying the effects of Pergoverisr; GONAL-fr; Recombinant human chorionic gonadotrophin (r-hCG) on Infertility in females ages 18 years to 41 years. This clinical trial is slated to start January 2014 and is expected to end circa May 2015.

+49 6151 72 5200
Merck KGaA Communication Center
Overall Study Contact Info
StatusName Contact Phone
RecruitingMerck KGaA Communication Centerservice@merckgroup.com+49 6151 72 5200

This study is officially titled, "A Phase III, Randomized, Controlled, Single-blind, Multicentre, Parallel Arm Trial to Assess the Efficacy and Safety of Pergoverisr (Follitropin Alfa and Lutropin Alfa) and GONAL-fr (Follitropin Alfa) for Multifollicular Development as Part of an Assisted Reproductive Technology Treatment Cycle in Poor Ovarian Responders, as Defined by the European Society of Human Reproduction and Embryology Criteria."

Locations

Please contact the Merck KGaA Communication Center located in

Darmstadt, Germany - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.